| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.24 | 6e-10 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-09 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.25 | 5e-07 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.22 | 1e-05 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.15 | 1e-05 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.15 | 1e-05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-05 |